CUE · Cue Biopharma Inc
United States · RS rating 44 · As of 2026-11-03
| Price | 20.86 USD |
|---|---|
| 1-day change | +7.4% |
| RS rating (overall / 1M / 3M / 12M) | 44 / 28 / 29 / 99 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 31 / 29 / 41 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +114.3% |
| Sales growth Q/Q | +921.0% |
| Distance from 52-week high | +44.9% |
| Market cap (USD) | $1.8M |